{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:10:09Z","timestamp":1790014209208,"version":"4.0.1"},"reference-count":57,"publisher":"BMJ","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 HL 116273"],"award-info":[{"award-number":["T32 HL 116273"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2026,7,29]]},"abstract":"<jats:p>While heart transplantation (HT) is the optimal therapy for end-stage heart failure patients, longevity of HT recipients continues to be limited by rejection and its sequelae. In this review, we provide an overview of current immunosuppressive principles and the prevention, diagnosis and treatment of rejection in HT. All HT recipients are maintained on immunosuppression to prevent rejection and undergo regular surveillance testing to identify rejection episodes that may require treatment. Risk of rejection is highest in the first year-post-HT and so during that period, immunosuppression is maintained at the highest levels and surveillance testing is done most frequently. The current standard triple-drug immunosuppressive regimen for HT consists of tacrolimus, a calcineurin inhibitor, mycophenolate mofetil, an antimetabolite agent and steroids. This regimen, with a calcineurin inhibitor as its cornerstone, has led to significantly decreased rates of rejection, particularly acute cellular rejection (ACR) in the current day compared with the early days of HT. The endomyocardial biopsy is currently the standard for rejection surveillance, but newer technologies such as donor-derived cell-free DNA measurements are changing surveillance practices in the field. While rates of ACR have decreased with current management strategies, antibody-mediated rejection (AMR) continues to pose a challenge. Newer immunosuppressive therapies that more effectively target the humoral and innate immune systems aim to better prevent and treat AMR in HT recipients. Furthermore, ongoing advancements in rejection surveillance strategy offer higher sensitivity and diagnostic accuracy for AMR compared with just histopathology on the endomyocardial biopsy. Ongoing advancements in immunosuppression and rejection surveillance will lead to continued improvement in longevity of HT recipients.<\/jats:p>","DOI":"10.1136\/heartjnl-2026-328009","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:20:29Z","timestamp":1790011229000},"page":"heartjnl-2026-328009","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Post-heart transplantation immunosuppression and rejection: what the general cardiologist needs to know"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7572-0091","authenticated-orcid":false,"given":"Rashmi","family":"Jain","sequence":"first","affiliation":[{"name":"Cardiology, Cedars-Sinai Medical Center, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5537-0573","authenticated-orcid":false,"given":"Michelle M","family":"Kittleson","sequence":"additional","affiliation":[{"name":"Cardiology, Cedars-Sinai Medical Center, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"2026092110201914000_heartjnl-2026-328009v1.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.12.012"},{"key":"2026092110201914000_heartjnl-2026-328009v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2017.08.021"},{"key":"2026092110201914000_heartjnl-2026-328009v1.3","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000093"},{"key":"2026092110201914000_heartjnl-2026-328009v1.4","doi-asserted-by":"crossref","first-page":"102614","DOI":"10.1016\/j.jchf.2025.102614","article-title":"Contemporary Antibody-Mediated Rejection in Heart Transplantation: JACC: Heart Failure Position Statement","volume":"13","author":"Mehta","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026092110201914000_heartjnl-2026-328009v1.5","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/TP.0000000000000246","article-title":"Time-dependent specificity of immunopathologic (C4d-CD68) and histologic criteria of antibody-mediated rejection for donor-specific antibodies and allograft dysfunction in heart transplantation","volume":"99","author":"Yerly","year":"2015","journal-title":"Transplantation"},{"key":"2026092110201914000_heartjnl-2026-328009v1.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2005.03.019"},{"key":"2026092110201914000_heartjnl-2026-328009v1.7","doi-asserted-by":"crossref","first-page":"S329","DOI":"10.1016\/j.ajt.2025.01.024","article-title":"OPTN\/SRTR 2023 Annual Data Report: Heart","volume":"25","author":"Colvin","year":"2025","journal-title":"Am J Transplant"},{"key":"2026092110201914000_heartjnl-2026-328009v1.8","doi-asserted-by":"crossref","first-page":"171","DOI":"10.21037\/cdt-20-289","article-title":"Evolution of heart transplantation since Barnard\u2019s first","volume":"11","author":"Javier","year":"2021","journal-title":"Cardiovasc Diagn Ther"},{"key":"2026092110201914000_heartjnl-2026-328009v1.9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.14797\/mdcvj.1596","article-title":"Immunosuppression Management in Heart Transplantation","volume":"21","author":"Habal","year":"2025","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"2026092110201914000_heartjnl-2026-328009v1.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2005.02.002"},{"key":"2026092110201914000_heartjnl-2026-328009v1.11","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199808270-00016"},{"key":"2026092110201914000_heartjnl-2026-328009v1.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01300.x"},{"key":"2026092110201914000_heartjnl-2026-328009v1.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01290.x"},{"key":"2026092110201914000_heartjnl-2026-328009v1.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.04.033"},{"key":"2026092110201914000_heartjnl-2026-328009v1.15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.4.2357"},{"key":"2026092110201914000_heartjnl-2026-328009v1.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.12.005"},{"key":"2026092110201914000_heartjnl-2026-328009v1.17","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13794","article-title":"Cardiac allograft vasculopathy: Insights on pathogenesis and therapy","volume":"34","author":"Lee","year":"2020","journal-title":"Clin Transplant"},{"key":"2026092110201914000_heartjnl-2026-328009v1.18","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1111\/ajt.12809","article-title":"Everolimus Initiation and Early Calcineurin Inhibitor Withdrawal in Heart Transplant Recipients: A Randomized Trial","volume":"14","author":"Andreassen","year":"2014","journal-title":"American Journal of Transplantation"},{"key":"2026092110201914000_heartjnl-2026-328009v1.19","doi-asserted-by":"crossref","unstructured":"Barten MJ , Hirt SW , Garbade J , et al . Comparing everolimus-based immunosuppression with reduction or withdrawal of calcineurin inhibitor reduction from six months after heart transplantation: the randomized MANDELA study. Am J Transplant 2019;3006\u201317. doi:10.1111\/ajt.15361","DOI":"10.1111\/ajt.15361"},{"key":"2026092110201914000_heartjnl-2026-328009v1.20","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/ajt.12181","article-title":"Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial","volume":"13","author":"Eisen","year":"2013","journal-title":"Am J Transplant"},{"key":"2026092110201914000_heartjnl-2026-328009v1.21","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000136812.90177.94"},{"key":"2026092110201914000_heartjnl-2026-328009v1.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1204166"},{"key":"2026092110201914000_heartjnl-2026-328009v1.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.03.499"},{"key":"2026092110201914000_heartjnl-2026-328009v1.24","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11020322","article-title":"Sirolimus-Based Immunosuppression Is Associated with Decreased Incidence of Post-Transplant Lymphoproliferative Disorder after Heart Transplantation: A Double-Center Study","volume":"11","author":"Asleh","year":"2022","journal-title":"J Clin Med"},{"key":"2026092110201914000_heartjnl-2026-328009v1.25","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.healun.2022.01.008","article-title":"The impact of induction therapy on mortality and treated rejection in cardiac transplantation: A retrospective study","volume":"41","author":"Bellumkonda","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"2026092110201914000_heartjnl-2026-328009v1.26","article-title":"Immunosuppressive T-cell antibody induction for heart transplant recipients","volume":"2013","author":"Penninga","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2026092110201914000_heartjnl-2026-328009v1.27","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14440","article-title":"Impact of induction therapy on outcomes after heart transplantation","volume":"35","author":"Tzani","year":"2021","journal-title":"Clin Transplant"},{"key":"2026092110201914000_heartjnl-2026-328009v1.28","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404683"},{"key":"2026092110201914000_heartjnl-2026-328009v1.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2015.04.001"},{"key":"2026092110201914000_heartjnl-2026-328009v1.30","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.healun.2023.05.005","article-title":"Intermediate-term outcomes of complement inhibition for prevention of antibody-mediated rejection in immunologically high-risk heart allograft recipients","volume":"42","author":"Coutance","year":"2023","journal-title":"J Heart Lung Transplant"},{"key":"2026092110201914000_heartjnl-2026-328009v1.31","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1161\/CIR.0000000000001155","article-title":"Dual-Organ Transplantation: Indications, Evaluation, and Outcomes for Heart-Kidney and Heart-Liver Transplantation: A Scientific Statement From the American Heart Association","volume":"148","author":"Kittleson","year":"2023","journal-title":"Circulation"},{"key":"2026092110201914000_heartjnl-2026-328009v1.32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02588.x"},{"key":"2026092110201914000_heartjnl-2026-328009v1.33","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.athoracsur.2019.02.012","article-title":"Heart-Kidney and Heart-Liver Transplantation Provide Immunoprotection to the Cardiac Allograft","volume":"108","author":"Chou","year":"2019","journal-title":"Ann Thorac Surg"},{"key":"2026092110201914000_heartjnl-2026-328009v1.34","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ads0255","article-title":"Cardiac allograft tolerance can be achieved in nonhuman primates by donor bone marrow and kidney cotransplantation","volume":"17","author":"Tonsho","year":"2025","journal-title":"Sci Transl Med"},{"key":"2026092110201914000_heartjnl-2026-328009v1.35","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/ctr.12827","article-title":"Induction immunosuppression for combined heart-lung transplantation","volume":"30","author":"Hayes","year":"2016","journal-title":"Clin Transplant"},{"key":"2026092110201914000_heartjnl-2026-328009v1.36","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.15420","article-title":"Contemporary Immunosuppression Management and 1-Year Outcomes in Dual Organ Heart Transplantation","volume":"38","author":"Huang","year":"2024","journal-title":"Clin Transplant"},{"key":"2026092110201914000_heartjnl-2026-328009v1.37","doi-asserted-by":"crossref","first-page":"107308","DOI":"10.1016\/j.ahj.2025.107308","article-title":"Incidence and risk factors for malignancy after heart transplantation- Analysis of the UNOS Registry","volume":"293","author":"Magod","year":"2026","journal-title":"Am Heart J"},{"key":"2026092110201914000_heartjnl-2026-328009v1.38","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1592"},{"key":"2026092110201914000_heartjnl-2026-328009v1.39","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000004323"},{"key":"2026092110201914000_heartjnl-2026-328009v1.40","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.ajt.2024.03.031","article-title":"Redefining the molecular rejection states in 3230 heart transplant biopsies: Relationships to parenchymal injury and graft survival","volume":"24","author":"Halloran","year":"2024","journal-title":"Am J Transplant"},{"key":"2026092110201914000_heartjnl-2026-328009v1.41","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.healun.2025.10.024","article-title":"Defining the relationships among four tests for assessing antibody-mediated rejection in heart transplants in a prospective, observational study","volume":"45","author":"Madill-Thomsen","year":"2026","journal-title":"J Heart Lung Transplant"},{"key":"2026092110201914000_heartjnl-2026-328009v1.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2022.11.002"},{"key":"2026092110201914000_heartjnl-2026-328009v1.43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912965"},{"key":"2026092110201914000_heartjnl-2026-328009v1.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2018.09.004"},{"key":"2026092110201914000_heartjnl-2026-328009v1.45","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.049098"},{"key":"2026092110201914000_heartjnl-2026-328009v1.46","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.15287","article-title":"The impact of active cytomegalovirus infection on donor-derived cell-free DNA testing in heart transplant recipients","volume":"38","author":"Alam","year":"2024","journal-title":"Clin Transplant"},{"key":"2026092110201914000_heartjnl-2026-328009v1.47","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.jcmg.2021.05.008","article-title":"Diagnostic Accuracy of Cardiovascular Magnetic Resonance for Cardiac Transplant Rejection: A Meta-Analysis","volume":"14","author":"Han","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026092110201914000_heartjnl-2026-328009v1.48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199806183382506"},{"key":"2026092110201914000_heartjnl-2026-328009v1.49","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2017060679"},{"key":"2026092110201914000_heartjnl-2026-328009v1.50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506027"},{"key":"2026092110201914000_heartjnl-2026-328009v1.51","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.healun.2025.04.023","article-title":"Efficacy and safety of belatacept in heart transplant recipients","volume":"44","author":"Baranowska","year":"2025","journal-title":"J Heart Lung Transplant"},{"key":"2026092110201914000_heartjnl-2026-328009v1.52","doi-asserted-by":"crossref","unstructured":"Buccieri EF , Urtis M , Tescari A , et al . AI-based identification of acute cellular rejection in digital pathology images of endomyocardial biopsies from heart transplanted patients. Eur Heart J 2025;46. doi:10.1093\/eurheartj\/ehaf784.4401","DOI":"10.1093\/eurheartj\/ehaf784.4401"},{"key":"2026092110201914000_heartjnl-2026-328009v1.53","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/ehjdh\/ztad016","article-title":"Prediction of heart transplant rejection from routine pathology slides with self-supervised deep learning","volume":"4","author":"Seraphin","year":"2023","journal-title":"Eur Heart J Digit Health"},{"key":"2026092110201914000_heartjnl-2026-328009v1.54","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/ehjdh\/ztad001","article-title":"Non-invasive detection of cardiac allograft rejection among heart transplant recipients using an electrocardiogram based deep learning model","volume":"4","author":"Adedinsewo","year":"2023","journal-title":"Eur Heart J Digit Health"},{"key":"2026092110201914000_heartjnl-2026-328009v1.55","doi-asserted-by":"crossref","DOI":"10.1038\/s43856-025-00999-0","article-title":"Machine learning-assisted assessment of extracellular vesicles can monitor cellular rejection after heart transplant","volume":"5","author":"Burrello","year":"2025","journal-title":"Commun Med (Lond)"},{"key":"2026092110201914000_heartjnl-2026-328009v1.56","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1097\/TP.0000000000005369","article-title":"Circulating Tissue Specific Extracellular Vesicles for Noninvasive Monitoring of Acute Cellular Rejection in Clinical Heart Transplantation","volume":"109","author":"Korutla","year":"2025","journal-title":"Transplantation"},{"key":"2026092110201914000_heartjnl-2026-328009v1.57","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.124.013141","article-title":"Identification of Heart Transplant Rejection Subtypes With Circulating MicroRNAs","volume":"19","author":"Goldberg","year":"2026","journal-title":"Circ Heart Fail"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2026-328009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:20:34Z","timestamp":1790011234000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2026-328009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":57,"alternative-id":["10.1136\/heartjnl-2026-328009"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2026-328009","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]}}}